Standard Biotools (LAB) financial statements
Standard Biotools reported revenue of $85M in fiscal 2025, down 2.2% a year over 9 years.
Net income was -$75M and the operating margin -129.2%, against -70.1% in 2016.
Free cash flow was -$83M.
The diluted share count rose 1216% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Standard Biotools's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $104M | $102M | $113M | $117M | $138M | $131M | $98M | $106M | $91M | $85M |
| Cost of revenue | $46M | $50M | $51M | $53M | — | — | $61M | $56M | $46M | $43M |
| Gross profit | $58M | $52M | $62M | $64M | — | — | $37M | $50M | $45M | $43M |
| Research and development | $38M | $31M | $30M | $32M | $36M | $38M | $37M | $26M | $29M | $26M |
| Selling, general and admin | $93M | $80M | $80M | $84M | $98M | $99M | $102M | $88M | $103M | $110M |
| Operating income | -$73M | -$58M | -$48M | -$52M | -$51M | -$67M | -$116M | -$77M | -$127M | -$110M |
| Interest expense | $6M | $6M | $14M | $4M | $4M | $4M | $4M | $5M | — | — |
| Pre-tax income | -$80M | -$64M | -$61M | -$67M | -$54M | -$64M | -$193M | -$74M | -$90M | -$97M |
| Income tax | -$4M | -$3M | -$2M | -$2M | -$1M | -$4M | -$3M | $452,000 | $542,000 | -$38M |
| Net income | -$76M | -$61M | -$59M | -$65M | -$53M | -$59M | -$190M | -$75M | -$139M | -$75M |
| EPS (diluted) | -$2.62 | -$1.84 | -$1.49 | -$0.97 | -$0.74 | -$0.78 | -$2.43 | -$0.94 | -$0.52 | -$0.20 |
| Diluted shares | 29M | 33M | 40M | 67M | 72M | 76M | 78M | 79M | 353M | 382M |
| Gross margin | 55.9% | 51.0% | 54.6% | 54.8% | — | — | 37.8% | 47.4% | 49.3% | 49.9% |
| Operating margin | -70.1% | -57.3% | -42.6% | -44.2% | -36.9% | -51.7% | -118.6% | -72.0% | -140.1% | -129.2% |
| Net margin | -72.8% | -59.4% | -52.2% | -55.3% | -38.4% | -45.4% | -194.1% | -70.2% | -152.6% | -87.8% |
Balance sheet
Fiscal years, from Standard Biotools's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $59M | $63M | $95M | $61M | $70M | $29M | $167M | $115M | $293M | $188M |
| Receivables | $15M | $15M | $17M | $19M | $25M | $18M | $17M | $20M | $15M | $13M |
| Inventory | $20M | $15M | $13M | $14M | $20M | $21M | $21M | $21M | $21M | $20M |
| Total current assets | $97M | $95M | $127M | $96M | $118M | $72M | $209M | $158M | $376M | $454M |
| Property, plant and equipment | $17M | $12M | $9M | $8M | $18M | $28M | $26M | $24M | $23M | $19M |
| Goodwill | $104M | $104M | $104M | $104M | $107M | $106M | $106M | $106M | $111M | — |
| Total assets | $306M | $287M | $304M | $265M | $325M | $275M | $390M | $323M | $612M | $568M |
| Total current liabilities | $30M | $33M | $38M | $33M | $54M | $50M | $43M | $109M | $66M | $108M |
| Total liabilities | $253M | $256M | $232M | $111M | $186M | $181M | $161M | $160M | $141M | $143M |
| Shareholders' equity | $53M | $31M | $72M | $154M | $139M | $95M | -$81M | -$148M | $472M | $424M |
| Net debt | -$35M | -$58M | -$95M | -$22M | -$69M | -$28M | -$81M | -$52M | -$167M | -$121M |
Cash flow
Fiscal years, from Standard Biotools's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39M | -$24M | -$25M | -$35M | -$15M | -$44M | -$89M | -$43M | -$143M | -$74M |
| Capital spending | $5M | $2M | $372,000 | $3M | $13M | $13M | $4M | $3M | $8M | $8M |
| Free cash flow | -$44M | -$26M | -$26M | -$38M | -$28M | -$57M | -$93M | -$46M | -$152M | -$83M |
| Stock-based compensation | $14M | $9M | $11M | $11M | $14M | $16M | $15M | $13M | $32M | $30M |
| Share buybacks (net) | — | — | — | — | — | $0 | -$563,000 | -$5M | -$40M | $0 |
| Net borrowing | — | $0 | $0 | $3M | $0 | -$501,000 | $0 | — | — | — |
| Free cash flow margin | -42.3% | -25.2% | -22.6% | -32.2% | -20.4% | -43.9% | -95.1% | -43.4% | -166.8% | -96.9% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LAB.
Open LAB in InvestinglyQuestions
What was Standard Biotools's revenue in 2025?
$85M in fiscal 2025, from its 10-K filing.
How much free cash flow does Standard Biotools generate?
-$83M in fiscal 2025 (operating cash flow minus capital spending).
From Standard Biotools's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.